APIXABAN'ın DOZA BAĞLI ANTİANJİYOJENİK POTANSİYELİ: Deneysel bir bakış

Aim: Direct oral anticoagulants (DOACs) are good alternatives to conventional medical regimens for the treatment and prevention of thromboembolism. Apixaban is one more popular variations these newly developed drugs. Aside from its anticoagulant potential, possible cellular effects remain a topic future studies. The object this study was investigate antiangiogenic apixaban in chorioallantoic membrane (CAM) model.Method: Drug pellets were prepared at 10-4, 10-5, 10-6 M concentrations placed on fourth day egg incubation. On eighth day, all vascular densities membranes compared with concentration bevacizumab, which known monoclonal, humanized, endothelial growth-factor inhibitor.Results: We find that 10-4 has strong potential similar bevacizumab. However, there moderate lower dose (10-5 M, M). A comparison higher doses (10-4 concentration) M) revealed significant statistical differences (p < 0.05).Conclusion: Our results indicate high potential. exact mechanism effect remains unknown. These pilot should be confirmed further studies obtain an updated look DOACs.